Virpax Pharmaceuticals announced that it has spun off a wholly-owned subsidiary called Novvae Pharmaceuticals that will develop Virpax’s over-the-counter products, starting with AnQlar antiviral nasal spray. Virpax acquired North American rights to AnQlar, which contains a mucoadhesive polymer derived from chitosan, from Nanomerics in August 2020 and expanded the deal to include worldwide rights in March 2022. The company’s pipeline also includes Envelta intranasal enkephelin for the treatment of pain and NobrXiol cannabidiol nasal spray for the treatment of pediatric epilepsy.
In August 2021, Virpax said that it had held a pre-IND meeting with the FDA regarding clinical development of AnQlar, a “molecular masking” nasal spray, as an OTC prophylactic against viral diseases. The company now says that Novvae will be responsible for clinical development of AnQlar.
Virpax Chairman and CEO Anthony P. Mack commented, “The formation of Novvae allows Virpax to focus exclusively on the development of its Rx product pipeline as we advance our lead product candidate, Probudur and prepare to enter Phase 2 human clinical trials in 2024. We are also looking to advance Envelta and expect to enter Phase 1 human clinical trials next year.”
Read the Virpax Pharmaceuticals press release.
